Docetaxel rechallenge associated with longer survival than cabazitaxel in selected metastatic prostate cancer patients
New observational evidence from a large US cohort suggests that, for men with metastatic castration-resistant…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Air pollution linked with worse cardiac remodelling and function in breast cancer patients receiving cardiotoxic therapy
Emerging evidence from a longitudinal cohort study published in JAMA Network Open suggests that exposure…
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target…
Model predicts long term mortality risk from prostate cancer
Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8…
Breast cancer risk markers linked to physical activity in adolescent girls
Recreational physical activity may be associated with breast tissue composition and biomarkers of stress in…
Study reveals how high blood pressure increases susceptibility to heart damage caused by a key cancer treatment
Anthracyclines are among the most widely used chemotherapy drugs and have been a mainstay of…
Many head and neck cancer trials end early. Why?
Head and neck cancer trials are frequently derailed before they can deliver answers. A new…
Global clinical trial landscape for children and adolescents with cancer
Clinical trials are essential to improving outcomes for children and adolescents with cancer, but access…
Which lung cancer subtypes are associated with different air pollutants?
A study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by…
PBS listing announced for treatment of unresectable or metastatic, well-differentiated extra-pancreatic or pancreatic neuroendocrine tumours
Ipsen Australia welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Cabometyx® (cabozantinib) for the treatment…